modernretina6d
Combination microdrops for ROP screening: Fewer systemic adverse events than standard mydriatrics
The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been ...
modernretina6d
Ocugen will continue second phase of OCU410 ArMaDa clinical trial
The ArMaDa clinical trial is currently being performed at 13 leading retinal surgery centers across the U.S. Dosing in the OCU410 ArMaDa clinical trial will be completed in early 2025 and the Company ...
modernretina5d
Topcon Healthcare appoints Jacques Gilbert to Chief Strategy and Business Development Officer
Jacques Gilbert has been appointed Chief Strategy and Business Development Officer for Topcon Healthcare Inc. According to the company, Jacques will lead the development and execution of Topcon ...